BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 18055314)

  • 21. Testing superiority at interim analyses in a non-inferiority trial.
    Chen YH; Chen C
    Stat Med; 2012 Jul; 31(15):1531-42. PubMed ID: 22438208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    Clin Trials; 2008; 5(4):364-5; author reply 365-6. PubMed ID: 18697851
    [No Abstract]   [Full Text] [Related]  

  • 24. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small sample approach, and statistical and epidemiological aspects.
    Offringa M; van der Lee H
    Handb Exp Pharmacol; 2011; 205():181-202. PubMed ID: 21882112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring clinical trials. Interim data should not be publicly available.
    Richards SM
    BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11778588
    [No Abstract]   [Full Text] [Related]  

  • 27. Reported quality of randomized controlled trials of physiotherapy interventions has improved over time.
    Moseley AM; Herbert RD; Maher CG; Sherrington C; Elkins MR
    J Clin Epidemiol; 2011 Jun; 64(6):594-601. PubMed ID: 21144705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures.
    Bretz F; Maurer W; Hommel G
    Stat Med; 2011 Jun; 30(13):1489-501. PubMed ID: 21290405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-inferiority study design: lessons to be learned from cardiovascular trials.
    Head SJ; Kaul S; Bogers AJ; Kappetein AP
    Eur Heart J; 2012 Jun; 33(11):1318-24. PubMed ID: 22564354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II trials: misleading and unreliable.
    Stewart DJ
    J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
    [No Abstract]   [Full Text] [Related]  

  • 31. Using the ROC curve for gauging treatment effect in clinical trials.
    Brumback LC; Pepe MS; Alonzo TA
    Stat Med; 2006 Feb; 25(4):575-90. PubMed ID: 16220481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Issues in clinical trial design: stopping a trial early and the large and simple trial.
    Thom EA; Klebanoff MA
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 1):619-25. PubMed ID: 16150252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the efficiency of targeted clinical trials.
    Maitournam A; Simon R
    Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive clinical trials for new drug applications in Japan.
    Ando Y; Hirakawa A; Uyama Y
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):175-9. PubMed ID: 20961739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
    Lai TL; Shih MC; Zhu G
    Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conservative sample size estimation in nonparametrics.
    De Martini D
    J Biopharm Stat; 2011 Jan; 21(1):24-41. PubMed ID: 21191852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Issues in the planning and conduct of randomised trials.
    Bhandari M; Pape HC; Giannoudis PV
    Injury; 2006 Apr; 37(4):349-54. PubMed ID: 16487524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blinded sample size reassessment in non-inferiority and equivalence trials.
    Friede T; Kieser M
    Stat Med; 2003 Mar; 22(6):995-1007. PubMed ID: 12627414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the Data and Safety Monitoring Committee (DSMC).
    Wilhelmsen L
    Stat Med; 2002 Oct; 21(19):2823-9. PubMed ID: 12325098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.